New immunotherapy combination significantly improves survival for hepatocellular carcinoma

An immunotherapy drug combination has improved survival in hepatocellular carcinoma by up to 42%. Results of a recent clinical trial show huge improvements in prognosis with atezolizumab and bevacizumab combination, which is now seeking US FDA approval.A recent clinical trial from the University of California, Los Angeles (CA, USA) has investigated the combination of atezolizumab (Tecentriq®), an immunotherapy treatment, with bevacizumab (Avastin®), an anti-angiogenesis drug, for the treatment of hepatocellular carcinoma. Their results demonstrate significant improvements in overall and progression-free survival, as well as increasing tumor regression. Currently, treatment options for hepatocellular carcinoma are limited and prognosis in advanced disease...